Pharma Focus Asia

Lonza to Open Two Additional Manufacturing Suites

Introduction:
Lonzaplans to open two additional manufacturing sites to expand the conjugation facility.

Features:
The expansion of additional two manufacturing suites aims for the development and manufacturing infrastructure for clinical and commercial supply. The new production suites are connected to theexisting conjugation facility.

The manufacturing suite covers approximately 1500m2 and adds 30 per cent additional capacity for clinical and commercial supply. Moreover, an additional 5000m2 space is designed for logistics, storage, and other supporting infrastructure to provide an optimal workflow.Therefore, the highly flexible setup makes use of single-use, stainless steel, and hybrid concepts for bioconjugation processes.

The laboratory space is extended to double the analytical and process development capacity.

With the opening of a new manufacturing suite expands the bioconjugation capacityand thus offering highly flexible solutions for a broad range of customers.

The construction of the bioconjugation capacity is scheduled to be fully operational for customers in the first half of 2022.

Specifications:

NameLonza
TypeNew Construction
Year2022

 

magazine-slider-image
magazine-slider-image
Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024